Trials / Completed
CompletedNCT03538314
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
A Phase I, Open-label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-line Malignant Melanoma Patients Planned for Treatment With Pembrolizumab
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Ultimovacs ASA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
UV1 is a therapeutic cancer vaccine that has been explored in prostate and lung cancers, and in combination with ipilimumab in malignant melanoma. This study will explore the safety, tolerability and efficacy of UV1 administered with GM-CSF in melanoma patients who are also receiving pembrolizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UV1 | UV1 (300 microgram) |
| DRUG | GM-CSF | GM-CSF (37,5 or 75 microgram) |
Timeline
- Start date
- 2018-07-09
- Primary completion
- 2022-10-01
- Completion
- 2024-06-15
- First posted
- 2018-05-29
- Last updated
- 2024-08-22
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03538314. Inclusion in this directory is not an endorsement.